Ra Medical Systems, Inc** (NYSE: RMED) announced two live cases and an expert panel presentation of clinical outcomes utilizing DABRA** for the treatment of peripheral artery disease (PAD) to occur at the C3 Global Summit.

"The DABRA excimer laser is a new technology which has added significant capability and options for our complex vascular patients," said Rajesh M. Dave, MD. "In my practice, DABRA has delivered successful outcomes, has proven to be safe with no reported cases of distal embolization, and is effective in dissolving variety of plaque types." Dr. Dave is Chairman of the Department of Cardiology, Geisinger Holy Spirit Hospital in Camp Hill, PA. He is also Chairman of the C3 Global Summit and Study Chairman of the DABRA RESULTS registry study.

The schedule of Ra Medical events is as follows:

- **Expert panel symposium, Monday, June 24 at 10:30 a.m.** in Salon BC as part of the endovascular track, featuring:
  - Mohammad Ansari, MD
  - Rajesh M. Dave, MD
  - Ashok Kondur, MD

- **Live case transmissions Monday, June 24:**
  - 11:00 am EDT Charles Bailey, MD, Heart Endovascular and Rhythm of Texas
  - 2:05 pm EDT Athar Ansari, MD, California Heart & Vascular Clinic

DABRA (Destruction of Arteriosclerotic Blockages by laser Radiation Ablation) is a novel, minimally invasive excimer laser system that non-thermally, photochemically ablates channels in vascular blockages. Unlike many mechanical, acoustic, or thermal treatments for PAD that may damage the arterial wall, DABRA dissolves blockages with minimal vascular trauma.

"By offering a safe and highly effective treatment for patients with PAD, the DABRA laser is helping physicians save the limbs and lives of their patients throughout the world," said Dean Irwin, CEO, Ra Medical Systems.

The Complex Cardiovascular Catheter Therapeutics (C3): Advanced Endovascular and Coronary Intervention Global Summit conference takes place from June 23 – 26 in Orlando, FL. C3 has been designed for physicians who specialize in interventional cardiology, vascular surgery, interventional radiology, podiatry, as well as fellows, residents, and other healthcare professionals interested in atherosclerotic cardiovascular disease. For more information, please visit Ra Medical Systems at Booth No. 206 at C3 or visit www.ramed.com.

**About Ra Medical Systems**

Ra Medical Systems is a commercial medical device company developing and marketing innovative excimer laser systems for the treatment of vascular and dermatologic diseases. DABRA launched in 2017 for the endovascular treatment of blockages resulting from lower extremity vascular disease. Pharos launched in 2004 for the treatment of dermatological disorders including psoriasis, vitiligo, and atopic dermatitis. DABRA and Pharos are based on Ra Medical’s core excimer laser technology platform that produces 308 nanometer light, a UVB wavelength that studies have demonstrated increases T-cell apoptosis, or cell death, which may produce a beneficial, targeted immunosuppressive effect. Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, California. The vertically integrated
facility is ISO 13485 certified and is licensed by the state of California to manufacture sterile, single-use catheters in controlled environments.

MIB Abstract ID Number: 55889

**To access this link the user must be signed into the MIB MarketTracks.**